|Systematic (IUPAC) name|
|Bioavailability||Close to 100%|
|Biological half-life||1.5 hours|
|Excretion||Renal 94% Feces 6%|
|ATC code||C10AB04 (WHO)|
|Molar mass||250.333 g/mol[[Script error: No such module "String".]]|
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.
- Increases activity of Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand' , a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides.
- Reduce triglyceride levels
- Reduce Very low density lipoprotein (VLDL) levels
- Modest reduction of Low density lipoprotein (LDL) levels
- Moderate increase in High density lipoprotein (HDL) levels
Nontherapeutic effects and toxicities
- GI distress
- Musculoskeletal pain
- Increased incidence of gallstone
- Increased risk of cancer
- Hyperlipidemia (Type III): Gemfibrozil is the drug of choice for therapy.
- Hypertriglyceridemia (Type IV): Gemfibrozil, though not as effective as niacin, is better tolerated.
Contraindications and Precautions
- Gemfibrozil should not be given to these patients:
- Hepatic dysfunction
- Renal dysfunction
- Gemfibrozil should be used with caution in these higher risk categories:
- Biliary Tract Disease
- Pregnant women
- Obese patients
- Native Americans
- Anticoagulants: Gemfibrozil potentiates the action of coumadin and indanedione anticoagulants.
- Statin drugs: Concomitant administration of fibrates (including gemfibrozil) with statin drugs increases the risk of muscle cramping, myopathy, and rhabdomyolysis.
- DrugBank Gemfibrozil
- NIH Gemfibrozil Drug Info}
- Lopid International Study
- Safety of Statins - Circulation. 2004;109:III-50 – III-57